For decades, medical training in the United States and Northern Europe treated vitamin supplementation and pharmacological analgesia as separate disciplines. If a patient presented with an acute lumbar strain, standard protocol dictated an NSAID such as ibuprofen or naproxen, occasionally paired with a muscle relaxant. Vitamins were relegated to dietary deficiency management. South of the Rio Grande and across major European research hubs, pharmacologists took a radically different path.
Beginning in the late 1980s and accelerating through the 2000s, clinical researchers recognized that peripheral nerve inflammation is rarely just a mechanical problem. When an intervertebral disc compresses a lumbar nerve root, the resulting pain stems from twin crises: an intense local inflammatory response driven by prostaglandin synthesis, and an immediate metabolic stall inside the nerve axon. Treating the swelling while ignoring the starving, misfiring nerve fiber prolonged recovery times and pushed patients toward chronic opioid or high-dose NSAID exposure.
Pharmaceutical manufacturers addressed this bottleneck by binding a full-spectrum neurotropic complex directly to diclofenac sodium. In Mexico and Central America, brands like Tribedoce (manufactured by Laboratorios Bruluart) became ubiquitous across public healthcare systems and private practices alike. What began as a regional mainstay has evolved into an internationally recognized protocol for acute radiculopathy, frequently sought out by medical travelers and evaluated in peer-reviewed clinical trials for its opioid-sparing properties.
